CLINICAL TRIAL HALF
Prospective phase II clinical trial evaluating the efficacy and safety of tyrosine kinase inhibitor discontinuation after prior two-step dose reduction in patients with chronic myeloid leukemia in deep molecular remission
The HALF clinical trial is designed as a prospective, multicentre, non-randomised, open-label phase II study to assess the efficacy and safety of tyrosine kinase inhibitor withdrawal after prior two-step dose reduction in patients with chronic myeloid leukaemia in deep remission. The HALF clinical trial could contribute to the formulation of a new disease management strategy for patients achieving sustained remission with the potential for wider benefits not only for the patients themselves but also for the healthcare system.
OVERVIEW OF RECRUITMENT
The planned number of subjects for the HALF study was 150 patients. This number was reached in January 2022. Recruitment was completed as of June 30, 2023 with a total of 221 patients enrolled. The infographic below shows the involvement of the collaborating sites in terms of number of subjects enrolled.
Important links to the project
Project documents
If you are interested in the full version of the ICF, or other KH documentation, please contact rychlickova@med.muni.cz
Contact
National coordinator of the HALF study:
doc. MUDr. Daniela Žáčková, Ph.D. | zackova.daniela@fnbrno.cz | +420 532 232 838
Project managers:
PharmDr. Jitka Rychlíčková, Ph.D., BCPS | rychlickova@med.muni.cz
PharmDr. Adéla Bártová | adela.bartova@med.muni.cz